Target family: Casein kinase 2 (CK2) family (type: enzyme)
Target: Casein kinase 2

Ligand: casein kinase II inhibitor III (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.960000038146973 pIC50
Reference (Journal): Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors.
Published in: Chembiochem

Ligand: compound 2 [PMID: 22560567] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 2 [PMID: 22560567] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Discovery of XL413, a potent and selective CDC7 inhibitor.
Published in: Bioorg Med Chem Lett

Ligand: compound 5b [PMID: 24900464] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization.
Published in: ACS Med Chem Lett

Ligand: CX-5011 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.010000228881836 pIC50
Reference (Journal): Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Published in: Biochemistry

Ligand: CX-5011 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.640000343322754 pIC50
Reference (Journal): Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Published in: Biochemistry

Ligand: CX-5279 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.5600004196167 pIC50
Reference (Journal): Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Published in: Biochemistry

Ligand: CX-5279 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.039999961853027 pIC50
Reference (Journal): Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Published in: Biochemistry

Ligand: DMAT (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.400000095367432 pKi

Ligand: DRB (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription.
Published in: J Biol Chem

Ligand: TBBt (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pKi
Reference (Journal): Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
Published in: Biochem J

Ligand: XL413 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.670000076293945 pIC50
Reference (Journal): Discovery of XL413, a potent and selective CDC7 inhibitor.
Published in: Bioorg Med Chem Lett